1. Locally Acquired (Autochthonous) Mosquito-Transmitted Plasmodium vivax Malaria - Saline County, Arkansas, September 2023.
- Author
-
Courtney AP, Boyanton BL Jr, Strebeck PV, Blount K, Ledford S, Ridpath AD, Mace KE, Smith C, Garner K, Waters C, Cima MJ, Patil N, McElroy PD, Raphael BH, Sapp SGH, Qvarnstrom Y, Lenhart A, Sutcliffe A, Dulski TM, and Rothfeldt L
- Subjects
- Animals, Humans, Arkansas, Plasmodium vivax isolation & purification, Travel, Malaria, Vivax diagnosis, Malaria, Vivax prevention & control, Malaria, Vivax transmission, Mosquito Vectors parasitology
- Abstract
A case of locally acquired (autochthonous) mosquito-transmitted Plasmodium vivax malaria was diagnosed in Arkansas in September 2023. This represents the 10th autochthonous case identified nationally in 2023, after 20 years without recorded local mosquitoborne malaria transmission in the United States. The public health response included case investigation, active case surveillance, mosquito surveillance and control, assessment of medical countermeasures, and clinical and public outreach. Prompt diagnosis and appropriate treatment of malaria can improve clinical outcomes and, in addition to vector control, minimize risk for local transmission. Clinicians should consider malaria among patients who have traveled to countries where malaria is endemic, or with unexplained fever regardless of travel history. Although the risk for autochthonous malaria in the United States remains very low, its reemergence highlights the importance of vectorborne disease preparedness and response. Examples of such efforts include improving awareness among clinicians, access to diagnostics and antimalarial medications, and capacity for mosquito surveillance and control. Collaboration and communication among CDC, health departments, local jurisdictions, clinicians, hospitals, laboratories, and the public can support rapid malaria diagnosis, prevention, and control. Before traveling internationally to areas where malaria is endemic, travelers should consult with their health care provider regarding recommended malaria prevention measures, including chemoprophylaxis and precautions to avoid mosquito bites, to reduce both personal and community risk., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Alison D. Ridpath reports ownership of stocks in the following companies: Johnson & Johnson, BioNtech SE, Protagonist Therapeutics, Imminic, Inc., Infinity Pharmaceuticals, Inc., Pfizer, Inc., Merck and Co., Inc., Amgen. Inc., and IQVIA Holdings, Inc. Bobby L. Boyanton Jr. reports receipt of consulting fees from Guidepoint Global, MedAvers, and QuidelOrtho, payment or honoraria from QuidelOrtho, and application for a patent from Siemens Atellica Instruments. No other potential conflicts of interest were disclosed.
- Published
- 2024
- Full Text
- View/download PDF